文献速递眼底病与葡萄膜炎

晚期新生血管性年龄相关性黄斑变性眼有意暂停治疗的结果

Outcomes of Intentionally Suspending Treatment in Eyes With Advanced Neovascular Age-Related Macular Degeneration.
PubMed 文献 · Am J Ophthalmol · 2023-07-28

这项回顾性队列研究纳入93例视力≤20/400的晚期新生血管性年龄相关性黄斑变性患者,由主治医师暂停抗VEGF注射,评估暂停后24个月内的视力与OCT转归;多数眼视力和解剖指标保持稳定,7眼(7.5%)在平均977天后重启治疗。

要点

  • 93眼中,暂停治疗至24个月时平均黄斑中心凹厚度、最大病灶直径、最大病灶厚度及视力均无显著变化。
  • 7眼(7.5%)在暂停治疗平均977(SD 450)天后重新开始抗VEGF治疗。
  • 作者认为,对视力≤20/400且主治医师判断继续治疗不太可能获益的晚期nAMD眼,暂停抗VEGF注射可能是合理的。

核心结论

  • 对视力≤20/400的晚期新生血管性年龄相关性黄斑变性眼,当主治医师认为额外治疗不太可能带来获益时,暂停抗VEGF注射可能是合理的。
  • 多数眼在暂停治疗后视力和解剖学表现保持稳定,但少数眼重新开始抗VEGF治疗,提示仍应监测疾病进展。

研究设计与样本

  • 回顾性队列研究,纳入93例新生血管性年龄相关性黄斑变性患者(93眼),最佳Snellen视力≤20/400,由主治医师暂停抗VEGF治疗。
  • 评估暂停治疗后最长24个月的视力与光学相干断层扫描(OCT)特征。

主要发现

  • 93眼在平均962(SD 562)天内平均接受16次抗VEGF注射。
  • 暂停治疗访视与24个月后比较,平均黄斑中心凹厚度163(SD 118,范围19-704)μm vs 164(SD 217,范围19-1468)μm,P = .97,无显著变化。
  • 最大病灶直径2547(SD 1294,范围134-5707)μm vs 2442(SD 1158,范围421-5305)μm,P = .43,无显著变化。
  • 最大病灶厚度194(SD 136,范围0-618)μm vs 205(SD 131,范围0-573)μm,P = .40,无显著变化。
  • 视力1.87(SD 0.37,20/1482)vs 1.94(SD 0.28,20/1741),P = .16,无显著变化;7眼(7.5%)在暂停治疗平均977(SD 450)天后重新开始治疗。

临床怎么用

  • 作者认为,对视力≤20/400且主治医师判断额外治疗不太可能获益的晚期新生血管性年龄相关性黄斑变性眼,暂停抗VEGF注射可能是合理的。
  • 作者指出,尽管多数眼暂停治疗后视力和解剖学表现保持稳定,但少数眼重新开始抗VEGF治疗,提示仍应监测疾病进展。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the outcomes of intentionally suspending anti-vascular endothelial growth factor (anti-VEGF) injections in eyes with advanced neovascular age-related macular degeneration (nAMD). DESIGN: Retrospective cohort study. METHODS: The study sample comprised 93 patients with nAMD and best available Snellen visual acuity (VA) ≤20/400 in which anti-VEGF treatment was suspended by the treating physician. VA and optical coherence tomography (OCT) characteristics were evaluated to determine visual and anatomical outcomes up to 24 months after treatment suspension. RESULTS: A total of 93 eyes from 93 patients who had received a mean of 16 anti-VEGF injections over a mean of 962 (SD 562) days were included. Comparing the treatment suspension visit to 24 months later, no significant change in mean central foveal thickness (163 [SD 118, range 19-704] μm vs 164 [SD 217, range 19-1468], P = .97), greatest lesion diameter (2547 [SD 1294, range 134-5707] μm vs 2442 [SD 1158, range 421-5305] μm, P = .43), greatest lesion thickness (194 [SD 136, range 0-618] μm vs 205 [SD 131, range 0-573] μm, P = .40), or VA (1.87 [SD 0.37], 20/1482, vs 1.94 [SD 0.28], 20/1741, P = .16) was found. In total, 7 eyes (7.5%) restarted treatment following a mean of 977 (SD 450) days after treatment suspension. CONCLUSIONS: Suspension of anti-VEGF injections in eyes with advanced nAMD and VA ≤20/400 may be reasonable in cases where the treating physician deems additional treatment is unlikely to provide benefit. Although the visual and anatomical findings remained stable after treatment suspension in most, a small number restarted anti-VEGF therapy, suggesting that eyes should still be monitored for disease progression.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Awh KC, Mahmoudzadeh R, Salabati M, et al. Outcomes of Intentionally Suspending Treatment in Eyes With Advanced Neovascular Age-Related Macular Degeneration. Am J Ophthalmol. 2023. PMID: 37517527. doi:10.1016/j.ajo.2023.07.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。